Mesirow Financial Investment Management Equity Management lowered its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 16.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 307,545 shares of the company’s stock after selling 61,810 shares during the quarter. Mesirow Financial Investment Management Equity Management owned about 0.41% of Myriad Genetics worth $8,940,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. BlackRock Inc. boosted its position in Myriad Genetics by 3.5% during the third quarter. BlackRock Inc. now owns 11,466,610 shares of the company’s stock valued at $527,464,000 after buying an additional 383,089 shares during the period. Baillie Gifford & Co. raised its stake in Myriad Genetics by 1.0% in the third quarter. Baillie Gifford & Co. now owns 9,547,193 shares of the company’s stock worth $439,171,000 after buying an additional 92,008 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Myriad Genetics by 4.4% during the third quarter. Vanguard Group Inc. now owns 8,656,933 shares of the company’s stock valued at $398,219,000 after purchasing an additional 365,697 shares in the last quarter. Vanguard Group Inc increased its stake in shares of Myriad Genetics by 4.4% during the third quarter. Vanguard Group Inc now owns 8,656,933 shares of the company’s stock valued at $398,219,000 after purchasing an additional 365,697 shares in the last quarter. Finally, Frontier Capital Management Co. LLC grew its holdings in shares of Myriad Genetics by 25.2% during the fourth quarter. Frontier Capital Management Co. LLC now owns 3,223,566 shares of the company’s stock valued at $93,709,000 after buying an additional 647,812 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.

Myriad Genetics stock opened at $29.07 on Monday. The company has a quick ratio of 2.68, a current ratio of 2.97 and a debt-to-equity ratio of 0.26. The stock has a market cap of $2.15 billion, a P/E ratio of 24.23, a PEG ratio of 1.91 and a beta of 0.71. Myriad Genetics, Inc. has a 12-month low of $26.05 and a 12-month high of $50.44.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, February 5th. The company reported $0.38 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.34 by $0.04. Myriad Genetics had a net margin of 3.25% and a return on equity of 9.79%. The business had revenue of $216.80 million during the quarter, compared to analyst estimates of $217.69 million. During the same quarter last year, the firm posted $0.31 earnings per share. The business’s revenue for the quarter was up 15.4% compared to the same quarter last year. As a group, equities research analysts predict that Myriad Genetics, Inc. will post 1.49 earnings per share for the current year.

MYGN has been the topic of several research reports. Zacks Investment Research upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $49.00 target price on the stock in a report on Tuesday, October 23rd. BidaskClub downgraded shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Saturday, November 3rd. Deutsche Bank lifted their price target on shares of Myriad Genetics from $37.00 to $43.00 and gave the company a “hold” rating in a report on Monday, November 5th. ValuEngine cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, November 8th. Finally, TheStreet cut shares of Myriad Genetics from a “b” rating to a “c” rating in a research note on Thursday, November 8th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Myriad Genetics has a consensus rating of “Hold” and an average target price of $39.87.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://theolympiareport.com/2019/02/11/myriad-genetics-inc-mygn-shares-sold-by-mesirow-financial-investment-management-equity-management.html.

About Myriad Genetics

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Recommended Story: What are the risks of holding treasury bonds?

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.